Match!
Joon Yeul Nam
Ewha Womans University
VirologyHepatitis BHepatocellular carcinomaMedicineGastroenterology
20Publications
5H-index
72Citations
What is this?
Publications 20
Newest
#1Joon Yeul Nam (Ewha Womans University)H-Index: 5
#2A. Reum Choe (Ewha Womans University)
Last. Jin Wook Chung (SNU: Seoul National University)H-Index: 54
view all 16 authors...
The decision of transarterial chemoembolization (TACE) initiation and/or repetition remains challenging in patients with unresectable hepatocellular carcinoma (HCC). The aim was to develop a prognostic scoring system to guide TACE initiation/repetition. A total of 597 consecutive patients who underwent TACE as their initial treatment for unresectable HCC were included. We derived a prediction model using independent risk factors for overall survival (OS), which was externally validated in an ind...
Source
#1Young Youn Cho (CAU: Chung-Ang University)H-Index: 11
#2Young Jun Chang (SNU: Seoul National University)H-Index: 22
Last. Yoon Jun Kim (SNU: Seoul National University)H-Index: 39
view all 9 authors...
Background/Aims: Renal toxicity is a concern in patients with chronic hepatitis B taking nucleotide analogues, such as adefovir (ADV) and tenofovir disoproxil fumarate (TDF). We sought to determine the long-term renal effects of nucleotide analogue treatment versus entecavir (ETV) treatment. Methods: In this retrospective single-center study, we selected 87 patients who were treated with ADV and subsequently with TDF from June 2008 to December 2013. ETV-treated patients were matched by treatment...
Source
#1Jun Sik Yoon (SNU: Seoul National University)H-Index: 2
#2Dong Hyun Sinn (SMC: Samsung Medical Center)H-Index: 23
Last. Jung-Hwan YoonH-Index: 46
view all 16 authors...
Background: For patients with hepatocellular carcinoma (HCC), the definition of refractoriness to transarterial chemoembolization (TACE), which might make them a candidate for systemic therapy, is still controversial. We aimed to derive and validate a tumor marker-based algorithm to define the refractoriness to TACE in patients with intermediate-stage HCC. Methods: This multi-cohort study was comprised of patients who underwent TACE for treatment-naive intermediate-stage HCC. We derived a predic...
1 CitationsSource
#1Yun Bin Lee (SNU: Seoul National University)H-Index: 12
#2Joon Yeul Nam (SNU: Seoul National University)H-Index: 5
Last. Jung-Hwan Yoon (SNU: Seoul National University)H-Index: 46
view all 14 authors...
Source
#1Hyeki ChoH-Index: 8
#2Young Jun ChangH-Index: 22
Last. Jung-Hwan YoonH-Index: 46
view all 12 authors...
Background and Goals:Although nonalcoholic fatty liver disease (NAFLD) is a risk factor of hepatocellular carcinoma (HCC), it is unclear whether NAFLD additionally increases the risk of HCC among chronic hepatitis B (CHB) patients. This study evaluated the association between NAFLD and the risk of H
1 CitationsSource
#1Young Youn Cho (CAU: Chung-Ang University)H-Index: 11
#2Jeong-Hoon Lee (SNU: Seoul National University)H-Index: 24
Last. Jong Hyun Yoon (SNU: Seoul National University)H-Index: 12
view all 11 authors...
: Nucleot(s)ide analogues (NAs) reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. However, the risk of HCC is reportedly higher for NA-treated patients than for patients in the inactive CHB phase. This study aimed to compare the long-term outcomes of CHB patients with NA-induced viral suppression and those of patients with inactive CHB. This retrospective study involved 1118 consecutive CHB patients whose HBV DNA level was continuously <2000 IU/mL during fo...
4 CitationsSource
#1Minjong Lee (Kangwon National University)H-Index: 18
#2Young Jun Chang (SNU: Seoul National University)H-Index: 22
Last. Yoon Jun Kim (SNU: Seoul National University)H-Index: 39
view all 18 authors...
Background/Aims:Guidelines recommend surveillance for hepatocellular carcinoma (HCC) recurrence at 3-month intervals during the first year after curative treatment and 6-month intervals thereafter in all patients. This strategy does not reflect individual risk of recurrence. We aimed to stratify risk of recurrence to optimize surveillance intervals 1 year after treatment. Methods:We retrospectively analyzed 1,316 HCC patients treated with resection/radiofrequency ablation at Barcelona Clinic Liv...
Source
#1Yun Bin Lee (SNU: Seoul National University)H-Index: 12
#2Joon Yeul Nam (SNU: Seoul National University)H-Index: 5
Last. Jung-Hwan Yoon (SNU: Seoul National University)H-Index: 46
view all 14 authors...
Whether a sustained virological response (SVR) improves long-term outcomes in chronic hepatitis C patients with earlier-stage fibrosis has not been established. We investigated the differential effect of SVR on the risk of outcomes according to hepatic fibrosis grade. Fibrosis grade was categorised using FIB-4: <1.45, low-probability of significant fibrosis; 1.45–3.25, intermediate-probability; and ≥3.25, high-probability. Primary and secondary endpoints were hepatocellular carcinoma (HCC) occur...
Source
#1Hyun-Jai Cho (SNU: Seoul National University)H-Index: 16
#2Hyuk Ahn (SNU: Seoul National University)H-Index: 22
Last. Jong Hyun Yoon (SNU: Seoul National University)H-Index: 12
view all 13 authors...
: Nucleos(t)ide analogues (NAs) have been shown to decrease the risk of hepatocellular carcinoma (HCC) recurrence. This study evaluated whether high-potency NAs (entecavir and tenofovir disoproxil fumarate [TDF]) reduce the risk of tumour recurrence more potently than low-potency NAs after curative treatment of hepatitis B virus (HBV)-related HCC. This study included 607 consecutive HBV-related HCC patients treated with surgical resection or radiofrequency ablation. The patients were categorized...
1 CitationsSource
#1Joon Yeul Nam (SNU: Seoul National University)H-Index: 5
#2Jeong-Hoon Lee (SNU: Seoul National University)H-Index: 24
Source
12